Core Insights - Biorad Medisys has launched its US subsidiary, Medtimo Inc, following the acquisition of business assets from ReShape Lifesciences, marking its entry into the US market [1][2] - The expansion aligns with Biorad Medisys' strategy to grow in regulated markets and enhance its product portfolio [2][4] - Medtimo will focus on two primary products: the Lap-Band® for weight loss and Stimel-03 for neurological rehabilitation, addressing the increasing demand in these areas [3][7] Company Overview - Biorad Medisys is an Indian medical technology company with a presence in over 50 countries and a workforce of more than 1,700 [6] - The company operates two manufacturing facilities in Pune and Bengaluru and is committed to global needs and innovation [6] - Biorad Medisys has received investments from True North and Kotak Alternate Asset Managers Limited [6] Medtimo Inc. Details - Medtimo Inc. offers a portfolio that includes the FDA-approved Lap-Band® System and a proprietary vagal neuromodulation system for treating type 2 diabetes [7] - The Obalon® balloon technology is also part of Medtimo's offerings, providing a non-surgical option for weight loss [7] - The leadership of Medtimo expresses confidence in the partnership with Biorad Medisys to accelerate growth and innovation [5]

Core Insights - ReShape Lifesciences has received a Notice of Allowance for a patent on a novel Diabetes Neuromodulation system, which aims to improve glycemic control and reduce medication dependence for Type 2 diabetes patients [1][2] - The patent will provide protection until April 12, 2039, and is part of a broader intellectual property portfolio that includes 62 issued or pending patents [2] - The Diabetes Neuromodulation technology utilizes proprietary vagus nerve block (vBloc™) technology to regulate blood glucose levels by modulating the vagus nerve's influence on the liver and pancreas [2][3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band systems and Obalon balloon technology [4] - The company is transitioning its assets, including the DBSN™ system, to Biorad Medisys, which will own the system following the asset purchase agreement [5] Technology and Research - The Diabetes Neuromodulation system is a minimally invasive implant that delivers bio-electronic neuromodulation to regulate plasma glucose levels [3] - Pre-clinical studies have demonstrated improved glycemic control in animal models of Type 2 diabetes, indicating the potential effectiveness of the technology [2]